Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Nephrology
•
Glomerulonephritis
How long do you continue maintenance immunosuppression in a patient with PR3 ANCA glomerulonephritis with pulmonary involvement?
Related Questions
Do you prefer a mycophenolate or tacrolimus based glucocorticoid-sparing regimen for patients with minimal change disease?
In which patients with MGUS do you recommend a kidney biopsy to evaluate for MGRS?
Do you extend the duration of maintenance therapy past 24 months for patients with ANCA glomerulonephritis who have multiple organ involvement?
Do you obtain spot urine protein or 24 hour urine protein quantification studies in pregnant patients who are found to have proteinuria on a standard urinalysis test?
What is your approach to immunosuppression in patients with preserved kidney function who are found to have nephrotic syndrome of unknown etiology and cannot safely undergo a kidney biopsy?
What is your approach to immunosuppressive treatment for patients with crescentic IgA vasculitis and kidney manifestations?
How do you approach the management of patients with suspected membranous lupus nephritis who are found to have positive PLA2R antibodies?
What would be the clinical role of SGLT-2 inhibitors for lupus nephritis given it has an indication for proteinuria related to CKD?
When would you recommend starting immunosuppression in patients diagnosed with Henoch-Schönlein purpura and IgA nephropathy who have proteinuria < 1 gram per day and eGFR > 60 mL/min who are already on ACEi and SGLT2i?
How do you choose between eculizumab and ravulizumab for patients with acute kidney injury from complement mediated thrombotic microangiopathy?
